Latisse is a drug owned by Abbvie Inc. It is protected by 16 US drug patents filed from 2013 to 2017 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 25, 2024. Details of Latisse's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8101161 | Method of enhancing hair growth |
May, 2024
(1 year, 4 months ago) |
Expired
|
| US7351404 | Method of enhancing hair growth |
May, 2024
(1 year, 4 months ago) |
Expired
|
| US8263054 | Method of enhancing hair growth |
Aug, 2023
(2 years ago) |
Expired
|
| US8038988 | Method of enhancing hair growth |
Aug, 2023
(2 years ago) |
Expired
|
| US8632760 | Method of enhancing hair growth |
Jan, 2023
(2 years ago) |
Expired
|
| US8758733 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(2 years ago) |
Expired
|
| US9216183 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(2 years ago) |
Expired
|
| US8986715 | Method of enhancing hair growth |
Jan, 2023
(2 years ago) |
Expired
|
| US9226931 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(2 years ago) |
Expired
|
| US8926953 | Method of enhancing hair growth |
Jan, 2023
(2 years ago) |
Expired
|
| US7388029 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2022
(3 years ago) |
Expired
|
| US8541466 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(4 years ago) |
Expired
|
| US8906962 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(4 years ago) |
Expired
|
| US9579270 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(4 years ago) |
Expired
|
| US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(12 years ago) |
Expired
|
| US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(13 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Latisse's patents.
Latest Legal Activities on Latisse's Patents
Given below is the list of recent legal activities going on the following patents of Latisse.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed
Critical | 29 Apr, 2024 | US8263054 |
| Expire Patent
Critical | 29 Jan, 2024 | US9216183 |
| Maintenance Fee Reminder Mailed
Critical | 14 Aug, 2023 | US9216183 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jun, 2023 | US8101161 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Mar, 2023 | US8038988 |
| Expire Patent
Critical | 16 Jan, 2023 | US8906962 (Litigated) |
| Maintenance Fee Reminder Mailed
Critical | 01 Aug, 2022 | US8906962 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8758733 |
| Expire Patent
Critical | 01 Nov, 2021 | US8541466 |
| Maintenance Fee Reminder Mailed
Critical | 17 May, 2021 | US8541466 |
FDA has granted several exclusivities to Latisse. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Latisse, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Latisse.
Exclusivity Information
Latisse holds 2 exclusivities. All of its exclusivities have expired in 2017. Details of Latisse's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 24, 2011 |
| M(M-140) | Sep 04, 2017 |
US patents provide insights into the exclusivity only within the United States, but
Latisse is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Latisse's family patents as well as insights into
ongoing legal events
on those patents.
Latisse's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Latisse's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 25, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Latisse Generic API suppliers:
Bimatoprost is the generic name for the brand Latisse. 11 different companies have already filed for the generic of Latisse, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Latisse's generic
How can I launch a generic of Latisse before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Latisse's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Latisse's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Latisse -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.0003 | 03 May, 2010 | 1 | 01 Dec, 2014 | 25 May, 2024 | Extinguished Deferred |
Alternative Brands for Latisse
Latisse which is used for promoting eyelash growth and treating hypotrichosis., has several other brand drugs using the same active ingredient (Bimatoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bimatoprost, Latisse's active ingredient. Check the complete list of approved generic manufacturers for Latisse
About Latisse
Latisse is a drug owned by Abbvie Inc. It is used for promoting eyelash growth and treating hypotrichosis. Latisse uses Bimatoprost as an active ingredient. Latisse was launched by Abbvie in 2008.
Approval Date:
Latisse was approved by FDA for market use on 24 December, 2008.
Active Ingredient:
Latisse uses Bimatoprost as the active ingredient. Check out other Drugs and Companies using Bimatoprost ingredient
Treatment:
Latisse is used for promoting eyelash growth and treating hypotrichosis.
Dosage:
Latisse is available in solution/drops form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.03% | SOLUTION/DROPS | Prescription | TOPICAL |